Ginsenoside Rb1 Enhances Plaque Stability and Inhibits Adventitial Vasa Vasorum via the Modulation of miR-33 and PEDF

Xiaoyan Yang, Lei Wang, Zihao Zhang, Jiayi Hu, Xiaoling Liu, Hao Wen, Minghao Liu, Xue Zhang, Hongyan Dai, Mei Ni, Rui Li, Rong Guo, Lei Zhang, Xiaorong Luan, Huili Lin, Mei Dong, Huixia LuFrontiers in Cardiovascular Medicine 2021 · DOI

Introduction

Atherosclerosis is characterized by the accumulation of plaques within arterial walls. While plaque size is a concern, the primary clinical danger is plaque vulnerability—the likelihood that a plaque will rupture and cause a heart attack or stroke. A critical factor in this instability is the pathological proliferation of the adventitial vasa vasorum (VV). These microscopic vessels, which normally nourish the outer arterial layers, can grow uncontrollably into the plaque, delivering inflammatory cells and promoting intraplaque hemorrhage.

Ginsenoside Rb1, a major active component of ginseng, has long been recognized for its cardiovascular benefits. This study investigates whether Rb1 can stabilize atherosclerotic plaques by targeting the vasa vasorum and the molecular pathways governing their growth, specifically focusing on the microRNA-33 (miR-33) and Pigment Epithelium-Derived Factor (PEDF) axis.

Methods

The researchers employed an Apolipoprotein E-deficient (ApoE−/−) mouse model, a standard for atherosclerosis research.

  1. Plaque Induction: Mice were fed a high-fat diet (HFD) for 20 weeks to establish significant atherosclerotic lesions.
  2. Treatment Groups: Following induction, mice received either a control vehicle or Ginsenoside Rb1 (50 mg/kg/day) via intraperitoneal injection for 4 weeks.
  3. Mechanistic Validation: To test the role of miR-33, a third group received Rb1 treatment along with a lentivirus to overexpress miR-33, effectively challenging the drug's mechanism.
  4. Analysis: Plaque burden was quantified using Oil Red O staining of the aorta. Plaque composition and stability were assessed via immunohistochemistry for inflammatory markers (MOMA-2), smooth muscle cells, and collagen. The vasa vasorum were visualized using tomato lectin perfusion.

Key Results

The study demonstrated that Ginsenoside Rb1 significantly impacts both plaque size and stability.

Plaque Reduction and Stabilization

Rb1 treatment led to a marked decrease in the total plaque area within the aorta. More importantly, it improved the vulnerability index—a ratio measuring lipids and macrophages against smooth muscle cells and collagen. Rb1-treated plaques were more fibrous and less inflammatory, indicating higher stability.

Ginsenoside Rb1 reduces plaque area, an effect reversed by miR-33 overexpression. (A) Representative images of Oil Red O-stained aortas. (B) Quantitative analysis of plaque area as a percentage of the total vessel surface.

Inhibition of Vasa Vasorum and Inflammation

A key finding was the significant reduction in adventitial vasa vasorum proliferation in the Rb1 group. By suppressing these "highways" for inflammatory infiltration, Rb1 also lowered the levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α within the arterial wall.

The miR-33/PEDF Pathway

The molecular mechanism was traced to a specific genetic toggle. Rb1 treatment downregulated miR-33, which in turn increased the expression of PEDF, a potent anti-angiogenic protein. When miR-33 was artificially overexpressed, the beneficial effects of Rb1—including plaque stabilization and VV suppression—were largely abolished, confirming that the Rb1 -> miR-33 -> PEDF pathway is central to its therapeutic action.

Discussion and Conclusion

This research identifies Ginsenoside Rb1 as a potent regulator of plaque stability. By modulating the miR-33/PEDF axis, Rb1 inhibits the pathological growth of the vasa vasorum and reduces vascular inflammation.

While these results in ApoE−/− mice are promising, limitations remain. Mouse plaques do not perfectly replicate the spontaneous rupture seen in humans. Furthermore, the study used intraperitoneal injections; future work must evaluate the efficacy and bioavailability of Rb1 through oral administration to determine its potential as a long-term clinical therapy for human atherosclerosis. Nevertheless, the study provides a clear mechanistic basis for the anti-atherosclerotic properties of ginseng components.

Summary updated

Abstract

<b>Background:</b> Atherosclerosis is closely associated with proliferation of the adventitial vasa vasorum, leading to the atherosclerotic plaque progression and vulnerability. In this report, we investigated the role of Ginsenoside Rb<sub>1</sub> (Rb<sub>1</sub>) on atherosclerotic plaque stabilization and adventitial vasa vasorum (VV) along with the mechanisms involved. <b>Methods and Results:</b> Apolipoprotein E-deficient (ApoE<sup>-/-</sup>) mice were fed with a high-fat diet for 20 weeks, and then Ginsenoside Rb<sub>1</sub> (50 mg/kg/d, intraperitoneal) was given for 4 weeks. Rb<sub>1</sub> treatment significantly inhibited adventitial VV proliferation, alleviated inflammation, decreased plaque burden, and stabilized atherosclerotic plaques in apoE<sup>-/-</sup> mice. However, the beneficial effects of Rb<sub>1</sub> on atherosclerotic lesion was attenuated by overexpression of miR-33. The analysis from atherosclerotic plaque revealed that Rb<sub>1</sub> treatment could result in an induction of Pigment epithelium-derived factor (PEDF) expression and reduction of the miR-33 generation. Overexpression of miR-33 significantly reverted the Rb<sub>1</sub>-mediated elevation of PEDF and anti-angiogenic effect. <b>Conclusions:</b> Ginsenoside Rb<sub>1</sub> attenuates plaque growth and enhances plaque stability partially through inhibiting adventitial vasa vasorum proliferation and inflammation in apoE<sup>-/-</sup> mice. The anti-angiogenic and anti-inflammation effects of Rb<sub>1</sub> are exerted via the modulation of miR-33 and its target gene PEDF.
BibTeX
@inproceedings{yang2021ginsenoside,
  author = {Xiaoyan Yang and Lei Wang and Zihao Zhang and Jiayi Hu and Xiaoling Liu and Hao Wen and Minghao Liu and Xue Zhang and Hongyan Dai and Mei Ni and Rui Li and Rong Guo and Lei Zhang and Xiaorong Luan and Huili Lin and Mei Dong and Huixia Lu},
  title = {{Ginsenoside Rb1 Enhances Plaque Stability and Inhibits Adventitial Vasa Vasorum via the Modulation of miR-33 and PEDF}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.654670},
}
Figure